Citadel Advisors’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $152K | Buy |
66,600
+26,300
| +65% | +$83.4K | ﹤0.01% | 11668 |
|
|
2025
Q4 | $161K | Buy |
40,300
+4,300
| +12% | +$23.9K | ﹤0.01% | 11232 |
|
|
2025
Q3 | $305K | Buy |
36,000
+4,600
| +15% | +$44.6K | ﹤0.01% | 10336 |
|
|
2025
Q2 | $354K | Sell |
31,400
-12,400
| -28% | -$114K | ﹤0.01% | 9419 |
|
|
2025
Q1 | $415K | Sell |
43,800
-55,700
| -56% | -$563K | ﹤0.01% | 8890 |
|
|
2024
Q4 | $1.12M | Sell |
99,500
-4,400
| -4% | -$77.3K | ﹤0.01% | 6773 |
|
|
2024
Q3 | $2.94M | Buy |
103,900
+31,800
| +44% | +$820K | ﹤0.01% | 4823 |
|
|
2024
Q2 | $1.38M | Sell |
72,100
-10,200
| -12% | -$260K | ﹤0.01% | 6004 |
|
|
2024
Q1 | $2.7M | Buy |
82,300
+43,500
| +112% | +$1.39M | ﹤0.01% | 4970 |
|
|
2023
Q4 | $1.28M | Buy |
38,800
+15,000
| +63% | +$424K | ﹤0.01% | 6191 |
|
|
2023
Q3 | $648K | Buy |
23,800
+11,100
| +87% | +$309K | ﹤0.01% | 7494 |
|
|
2023
Q2 | $385K | Sell |
12,700
-9,300
| -42% | -$301K | ﹤0.01% | 8493 |
|
|
2023
Q1 | $714K | Buy |
22,000
+700
| +3% | +$22.1K | ﹤0.01% | 7517 |
|
|
2022
Q4 | $598K | Sell |
21,300
-24,200
| -53% | -$694K | ﹤0.01% | 7866 |
|
|
2022
Q3 | $1.64M | Buy |
45,500
+29,100
| +177% | +$1.03M | ﹤0.01% | 5980 |
|
|
2022
Q2 | $504K | Buy |
+16,400
| New | +$478K | ﹤0.01% | 8631 |
|
|
2022
Q1 | – | Sell |
-111,300
| Closed | -$3.08M | – | 13851 |
|
|
2021
Q4 | $3.08M | Sell |
111,300
-144,700
| -57% | -$4.15M | ﹤0.01% | 5285 |
|
|
2021
Q3 | $7.94M | Buy |
256,000
+195,700
| +325% | +$4.7M | ﹤0.01% | 3470 |
|
|
2021
Q2 | $1.27M | Sell |
60,300
-25,900
| -30% | -$519K | ﹤0.01% | 7713 |
|
|
2021
Q1 | $1.74M | Buy |
86,200
+22,400
| +35% | +$426K | ﹤0.01% | 6736 |
|
|
2020
Q4 | $1.02M | Sell |
63,800
-8,700
| -12% | -$115K | ﹤0.01% | 6752 |
|
|
2020
Q3 | $900K | Sell |
72,500
-1,700
| -2% | -$20K | ﹤0.01% | 6228 |
|
|
2020
Q2 | $528K | Buy |
74,200
+44,900
| +153% | +$301K | ﹤0.01% | 6974 |
|
|
2020
Q1 | $159K | Sell |
29,300
-7,800
| -21% | -$69.7K | ﹤0.01% | 8233 |
|
|
2019
Q4 | $336K | Sell |
37,100
-26,900
| -42% | -$219K | ﹤0.01% | 7421 |
|
|
2019
Q3 | $460K | Sell |
64,000
-171,000
| -73% | -$1.23M | ﹤0.01% | 6892 |
|
|
2019
Q2 | $1.87M | Sell |
235,000
-40,000
| -15% | -$474K | ﹤0.01% | 4629 |
|
|
2019
Q1 | $3.46M | Buy |
275,000
+255,200
| +1,289% | +$4.04M | ﹤0.01% | 3524 |
|
|
2018
Q4 | $395K | Buy |
19,800
+8,500
| +75% | +$197K | ﹤0.01% | 6782 |
|
|
2018
Q3 | $321K | Sell |
11,300
-9,400
| -45% | -$224K | ﹤0.01% | 7454 |
|
|
2018
Q2 | $436K | Buy |
20,700
+1,300
| +7% | +$24.6K | ﹤0.01% | 6609 |
|
|
2018
Q1 | $276K | Buy |
+19,400
| New | +$278K | ﹤0.01% | 6871 |
|
|
2016
Q1 | – | Sell |
-3,000
| Closed | -$36K | – | 7092 |
|
|
2015
Q4 | $36K | Buy |
+3,000
| New | +$44.2K | ﹤0.01% | 7544 |
|
Other funds holding EVH
CCM
RF
EC
VCM
RSCM
Citadel Advisors's EVH Position: Q1 2026 in Review
Citadel Advisors reduced its Evolent Health (EVH) stake by 62% in Q1 2026, selling an estimated $3.65M and leaving 705,222 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #6570.
Citadel Advisors first reported a position in EVH in Q2 2015 and has held it in 40 quarters since. The position peaked at $73M in Q4 2022. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.
- Citadel Advisors held 705,222 shares of Evolent Health worth $1.61M as of Q1 2026.
- Citadel Advisors sold 1,149,795 Evolent Health shares in Q1 2026, an estimated $3.65M.
- Evolent Health made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6570 holding.
- Citadel Advisors first reported a position in Evolent Health in Q2 2015 and has held it in 40 quarters since.
- Citadel Advisors's Evolent Health position peaked at $73M in Q4 2022.
- 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.